Code Llama, Meta's code-generating AI model, launches as open-source and for commercial use
Bay Area Times
August 25, 2023
Brought to you by:
Top stories today:
- Code Llama, Meta's code-generating AI model, launches
- Hugging Face confirms $235M fundraising by Google, NVIDIA
- Semaglutide produces “largest benefit ever” for heart failure
- Trump returns to Twitter with mugshot photo after 2-year hiatus
- China's imports of chipmaking equipment surge ahead of curbs
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 close (4 PM ET / 1 PM PT).
All times are ET.
1. Code Llama, Meta's code-generating AI model, launches as open-source and for commercial use
Supports most popular languages: “Python, C++, Java, PHP, Typescript (Javascript), C#, Bash and more.”
3 model sizes: 7B, 13B, and 34B.
100K tokens of context (input).
500B tokens was the size of the training set.
Code Llama – Python and Code Llama – Instruct are 2 fine-tuned versions of the model. - The Verge, Meta, paper
Code Llama performs similarly to GPT-3.5 Turbo, but worse than GPT-4
2. Hugging Face confirms $235M fundraising by Salesforce, Google, Amazon, NVIDIA
It now jumps to the #5 most valued generative AI unicorn:
GitHub for AI models.
100x+ ARR.
10K customers, 50K organizations, 1M repos. - Techcrunch
Say hello to JOYMODE. One) because it’s fun to say. Seriously, say, “Hello JOYMODE” aloud. Two) because they make an awesome, all natural, sexual performance booster that will help you get your best erections and enhance performance in the bedroom.
It’s like a pre-workout, but for sex. You mix in a glass of water, drink it 45 minutes to 5 hours before sex, and enjoy better blood flow, better erection quality & firmness, and increased sex drive. JOYMODE was designed by doctors who wanted a healthy and natural alternative to prescriptions like Viagra.
No doctor’s office. No prescription required. And it actually works.
*Sponsored.
4. Semaglutide (Ozempic/Wegovy) produces “largest benefit ever” for patients with heart failure subgroup
It is likely that tirzepatide (Mounjaro) will be even better, given it is more efficacious against weight loss
Why are governments taking so long to approve tirzepatide?
Only U.S., EU, and Australia have approved the drug. - Wikipedia
5. Trump returns to Twitter with mugshot photo after 2-year hiatus
Trump owns competitor Truth Social and had an agreement to only post on other platforms with a 6-hour lag
The exclusivity agreement appeared to have expired: “From December 22, 2021, until the expiration of 18 months thereafter, (the “TMTG Social Media Exclusivity Term”), President Trump has agreed to first channel any and all social media communications and posts coming from his personal profile to the Truth Social platform.”
“In the event of a force majeure as described in the License Agreement that lasts longer than 30 days, President Trump shall have the right to invoke the suspension of the “DJT/TMTG Social Media 6-Hour Exclusive.” - Reuters, SEC filing
6. China's imports of chipmaking equipment surge ahead of export curbs
July 23: when Japan started enforcing export restrictions.
Sep. 1: when Netherlands will kick off its enforcement. - FT
7. Interesting tweets, memes, and videos
Jay Powell spotted at Jackson Hole:
8. Other headlines
AI
OpenAI names Scale AI “preferred partner” to fine-tune GPT-3.5 Turbo.
Modular raises $100M for AI developer tools.
Ideogram, text-to-image AI, launches with $16.5M, led by a16z.
8 startups challenging NVIDIA in AI chips.
Tech
OnlyFans GMV +17% YoY to $5.6B in 2022.
Shein acquiring 1/3 of Forever 21's parent.
Amazon in talks with Disney about streaming ESPN at $20-35/mo.
Better falls 93% after SPAC public offering.
RNC's lawsuit against Google is dismissed by federal judge.
Drones: Walmart, Alphabet's Wing to test 6-mile deliveries.
WeWork lenders, funds discuss potential bankruptcy plan.
Uber raises minimum age for new CA drivers to 25, citing insurance costs.
Affirm revenue +23% to $446M in Q2, net result worsens to -$206M.
Dropbox ends unlimited storage, capping top plan at 5TB/user.
Threads reiterates promise to be integrated into fediverse.
Biotech
4% longer lifespan in mice after naked mole rat gene transfer.
Rejuve Biotech leverages long-lived fly data to develop drugs.
Neuronascent gets NIA grant for Phase 2 trial.
Cancer recurrence is target of ARCH's latest biotech, TFC.
Business
China stimulus rally last 10min, after Beijing announces stimulus.
Fed rates close to peak: Fed officials at Jackson Hole.
1% downpayment: Zillow's new offer as mortgage rates hit high.
SpaceX sued by DOJ for alleged bias, likely just followed laws.
Heineken sells Russian business for $1.
Leveraged loans not securities: federal appeals court.
CNN Max is new streaming channel on Warner's Max.
Michael Jordan now worth $3.5B, richest basketball player ever.
T-Mobile to lay off 7% of workforce, 5K employees.
Crypto
Binance halts credit card issuance after Visa, MasterCard step back.
SBF likely not to get Adderall in prison.
Vessel Capital launches with $55M in VC fund.
U.S. politics
Trump replaces Georgia lawyer before surrendering, has mugshot taken.
Rep. Jim Jordan launches probe into Georgia prosecution.
Maui sues Hawaiian Electric for allegedly starting fire.
Vivek consolidates as #2 in GOP race.
13M tuned into FOX to watch GOP debate.
World
Prigozhin's crash likely bomb ordered by Putin: U.S. officials.
F-16 training by U.S. for Ukrainians to start in Oct.
Saudi Arabia looks for China to build nuclear plant.
China launches “anti-corruption” crackdown on health sector.
Taiwan President requests military budget of $14B, 2% of GDP.
Was this newsletter forwarded to you? Sign up here. Liked it? Forward it to friends and get rewards (see below).
What did you think of today's newsletter? |
Disclaimer: The Bay Area Times is a news publisher. All statements and expressions herein are the sole opinions of the authors or paid advertisers. The information, tools, and material presented are provided for informational purposes only, are not financial advice, and are not to be used or considered as an offer to buy or sell securities; and the publisher does not guarantee their accuracy or reliability. You should do your own research and consult an independent financial adviser before making any investments. Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein. Assets mentioned may be owned by members of the Bay Area Times team.
Please read our Terms of Service and our Privacy Policy before using Our Service.